In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

Basit Öğe Kaydı
dc.authoridBeksac, Meral/0000-0003-1797-8657
dc.authoridBazarbachi, Ali/0000-0002-7171-4997
dc.authoridDrozd-Sokolowska, Joanna/0000-0002-4562-6264
dc.authoridPoire, Xavier/0000-0003-1897-0227
dc.authoridPabst, Thomas/0000-0002-6055-5257
dc.authorwosidTholouli, Eleni/KBB-6574-2024
dc.authorwosidBeksac, Meral/D-6411-2013
dc.authorwosidDrozd-Sokolowska, Joanna/AAZ-9805-2021
dc.contributor.authorBeksac, Meral
dc.contributor.authorEikema, Diderik-Jan
dc.contributor.authorKoster, Linda
dc.contributor.authorHulin, Cyrille
dc.contributor.authorPoire, Xavier
dc.contributor.authorHamladji, Rose-Marie
dc.contributor.authorGromek, Tomasz
dc.date.accessioned2024-05-19T14:50:35Z
dc.date.available2024-05-19T14:50:35Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised to intensify conditioning in autologous hematopoietic stem cell transplantation (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel with Mel200 during upfront AHCT. Between 2010 and 2017, MM patients who received Vel-Mel (n = 292) conditioning were compared with 4,096 Mel200 patients in the same 58 centres. Pre-AHCT, compared to Mel200 patients, Vel-Mel patients had similar International Staging System (ISS) scores and cytogenetic risk profiles; a similar proportion had received bortezomib-based induction (85% and 87.3%, respectively) though they were younger with a better performance status. Vel-Mel patients were more likely to achieve CR post-induction (40.6% vs 20.3%, p < 0.001) and by day 100 of AHCT (CR/VGPR: 70.2 % vs. 57.2%, p < 0.001). There was no difference in 3-year PFS (49% vs 46%, p = 0.06) or early post-AHCT mortality. In multivariable analysis, Vel-Mel associated with inferior PFS (HR: 1.69 (1.27-2.25, p < 0.001) and OS (HR:1.46 (1.14-1.86,p = 0.002), similar to negative effects on PFS of advanced ISS (HR:1.56 (1.33-1.83, p < 0.001), high-risk cytogenetics (HR:1.43(1.18-1.74, p < 0.001) and poor post-induction response(<=PR)(HR: 1.43(1.25-1.62, p < 0.001) Overall, despite superior pre- and post-AHCT responses, there was no improvement in PFS or OS following Vel-Mel. This data supports the findings of the smaller prospective IFM study.en_US
dc.description.sponsorshipScientific and Technological Research Councilof Turkiye (TUBITAK)en_US
dc.description.sponsorshipOpen access funding provided by the Scientific and Technological Research Councilof Turkiye (TUBITAK).en_US
dc.identifier.doi10.1038/s41409-023-02160-8
dc.identifier.endpage533en_US
dc.identifier.issn0268-3369
dc.identifier.issn1476-5365
dc.identifier.issue4en_US
dc.identifier.pmid38297040en_US
dc.identifier.startpage526en_US
dc.identifier.urihttps://doi.org10.1038/s41409-023-02160-8
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5752
dc.identifier.volume59en_US
dc.identifier.wosWOS:001155384200001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofBone Marrow Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectHigh-Dose Melphalanen_US
dc.subjectStem-Cell Transplantationen_US
dc.subjectAutologous Transplantationen_US
dc.subject200 Mg/M(2)en_US
dc.subjectPreparative Regimenen_US
dc.subjectPhase I/Iien_US
dc.subjectBusulfanen_US
dc.subjectTrialen_US
dc.titleIn the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMTen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu